ACCEL Lite: STRENGTH: High-Dose Omega-3 Fatty Acids vs. Corn Oil

Apr 20, 2021   |  Alison Bailey, MD, FACC; Steven E. Nissen, MD, MACC; Stephen J. Nicholls, MBBS, PhD, FACC; Michael Brian Mikolaj, MD, MPH, FACC

Podcast

Font Size
A
A
A

The benefits and risks of fish oil derivatives remain controversial. STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia) showed no benefits from administration of high doses of a carboxylic formulation containing both eicosapentaenoic acid and docosahexaenoic acid, but it did show an increase in risk of atrial fibrillation. In this interview, Steven E. Nissen MD, MACC; Stephen J. Nicholls MBBS, PhD, FACC; and Michael Mikolaj MD, MPH, FACC, discuss STRENGTH and whether omega-3 fatty acids produce net benefit or harm.

Like what you hear? ACCEL Subscribers enjoy 20+ insider interviews like these every month, with CME/MOC credit and other exclusive benefits. Subscribe today for more, and check out what's new at www.acc.org/ACCEL.




Clinical Topics: Dyslipidemia, Prevention, Lipid Metabolism, Nonstatins

Keywords: ACCELLite, Primary Prevention, Fatty Acids, Omega-3, Corn Oil, Fish Oils


< Back to Listings